GERRIT LOS was named vice president of pharmacology at AnaptysBio Inc.
Los will lead translational biology across the company’s antibody pipeline, including programs focused in immuno-oncology. Los will report to Macro Londei, AnaptysBio’s chief development officer.
Los joins AnaptysBio from Five Prime Therapeutics, where he led translational medicine across several immuno-oncology related biologics. Prior to Five Prime, Los was head of cancer biology at Pfizer, where he directed teams responsible for the development of several targeted cancer therapeutics, including crizotinib, axitinib and palbociclib.
Prior to Pfizer, Los was an adjunct professor at the University of California San Diego where his work focused on identifying response markers in cancer.
